IRIS
CIARDIELLO, DAVIDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.463
AS - Asia 1.152
NA - Nord America 947
SA - Sud America 113
AF - Africa 13
Totale 4.688
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.909
US - Stati Uniti d'America 925
SG - Singapore 407
CN - Cina 247
IT - Italia 201
HK - Hong Kong 186
IE - Irlanda 152
VN - Vietnam 125
BR - Brasile 94
DE - Germania 77
KR - Corea 62
IN - India 48
GB - Regno Unito 28
JP - Giappone 25
FR - Francia 21
FI - Finlandia 16
AT - Austria 14
PK - Pakistan 14
CA - Canada 13
NL - Olanda 11
PL - Polonia 11
CZ - Repubblica Ceca 6
EC - Ecuador 6
MX - Messico 6
AR - Argentina 5
TR - Turchia 5
ID - Indonesia 4
IQ - Iraq 4
MA - Marocco 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
BD - Bangladesh 3
PH - Filippine 3
SE - Svezia 3
BO - Bolivia 2
CL - Cile 2
CO - Colombia 2
DO - Repubblica Dominicana 2
ES - Italia 2
GI - Gibilterra 2
GR - Grecia 2
JO - Giordania 2
KE - Kenya 2
TH - Thailandia 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BE - Belgio 1
CH - Svizzera 1
CY - Cipro 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 4.688
Salva come PNG Salva come JPEG
Città #
Moscow 708
Singapore 226
San Jose 195
Hong Kong 181
Dublin 146
Santa Clara 126
Naples 75
Ashburn 73
Chandler 67
Seoul 62
Hefei 59
New York 45
Ho Chi Minh City 41
Beijing 40
Munich 40
Dallas 33
Bengaluru 32
Los Angeles 32
Hanoi 30
Haiphong 12
Bremen 11
Princeton 9
Rawalpindi 9
Roxbury 9
São Paulo 9
The Dalles 9
Turku 9
Warsaw 9
Da Nang 8
Cambridge 7
San Francisco 7
Vienna 7
Amsterdam 6
Frankfurt am Main 6
London 6
Nuremberg 6
Boardman 5
Changsha 5
Giugliano in Campania 5
Lappeenranta 5
Manchester 5
Milan 5
Atlanta 4
Brooklyn 4
Caserta 4
Chennai 4
Elora 4
Ercolano 4
Falkenstein 4
Hillsboro 4
Hải Dương 4
Mumbai 4
Orem 4
Shanghai 4
Tokyo 4
Baku 3
Bari 3
Battipaglia 3
Belo Horizonte 3
Boston 3
Brno 3
Central 3
City of London 3
Colle di Val d'Elsa 3
Council Bluffs 3
Guayaquil 3
Istanbul 3
Montpellier 3
Montreal 3
Nha Trang 3
Rio de Janeiro 3
Seattle 3
Shenzhen 3
Tianjin 3
Afragola 2
Amman 2
Anantapur 2
Andover 2
Anápolis 2
Baghdad 2
Bangkok 2
Barcellona Pozzo di Gotto 2
Bologna 2
Botucatu 2
Brdo 2
Bắc Giang 2
Campo Grande 2
Canoas 2
Castellammare di Stabia 2
Cercola 2
Chicago 2
Duque de Caxias 2
Fairfield 2
Grand Rapids 2
Guangzhou 2
Helsinki 2
Isernia 2
Johannesburg 2
La Paz 2
Limburg an der Lahn 2
Totale 2.541
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 219
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 159
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 158
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 158
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 157
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 157
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 154
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 150
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 150
Clinical management of metastatic colorectal cancer in the era of precision medicine 149
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 148
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 144
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review 142
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 141
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 139
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 138
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 134
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 131
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 129
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 126
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 124
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 124
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 120
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 120
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 115
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 114
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 112
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 112
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 107
Targeting the EGFR signalling pathway in metastatic colorectal cancer 84
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer 18
MRI-based radiomics for preoperative T-staging of rectal cancer: a retrospective analysis 14
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives 9
Totale 4.755
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 2 0
2021/202268 0 2 1 1 5 0 0 0 2 3 30 24
2022/2023321 19 6 9 28 31 27 3 24 146 4 20 4
2023/2024226 22 8 8 14 47 48 7 5 8 6 21 32
2024/2025784 27 27 26 56 108 117 80 77 84 62 64 56
2025/20263.346 174 187 162 101 326 1.798 206 183 133 76 0 0
Totale 4.755